UroGen officer Degnan proposes $89.6K share sale

The stated purpose of the sale is to cover tax withholding obligations upon vesting of equity awards.

Rhea-AI Filing Summary

UroGen Pharma Ltd. officer Christopher Degnan reported a proposed sale of 2,202 ordinary shares, with an aggregate market value of $89,621.40 and an approximate sale date of October 8, 2026. The notice lists 8,966 ordinary shares issued upon vesting of RSUs for no consideration. Meirav Shemesh, Authorized Signatory, Oppenheimer Israel (pursuant to delegation), signed the notice.

Key Figures

Ordinary shares to be sold: 2,202 shares Aggregate market value: $89,621.40 Ordinary shares outstanding: 48,721,701 shares +1 more

4 metrics

Ordinary shares to be sold 2,202 shares Proposed sale; approximate date October 8, 2026

Aggregate market value $89,621.40 Proposed sale of ordinary shares

Ordinary shares outstanding 48,721,701 shares UroGen Pharma Ltd.

Shares issued upon vesting of RSUs 8,966 shares Issued for no consideration

Key Terms

Rule 144, RSUs, tax withholding obligations

3 terms

Rule 144 regulatory

"definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

RSUs financial

"Shares issued upon vesting of RSUs"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

tax withholding obligations financial

"Shares sold to cover tax withholding obligations"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many URGN shares does Christopher Degnan plan to sell?

The notice lists a proposed sale of 2,202 ordinary shares by UroGen Pharma Ltd. officer Christopher Degnan, with an aggregate market value of $89,621.40 and an approximate sale date of October 8, 2026.

Why is Christopher Degnan selling URGN shares?

The stated purpose is to cover tax withholding obligations upon vesting of equity awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/09/2026 - 06:24 AM Accepted by SEC EDGAR 10/09/2026 - 06:23 AM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001741968
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	UroGen Pharma Ltd.
SEC File Number	001-38079
Address of Issuer	9 HA'TA'ASIYA ST RA'ANANA, ISRAEL 4365007
Phone	972 9 770 7601
Name of Person for Whose Account the Securities are To Be Sold	Christopher Degnan
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary shares	Oppenheimer & Co. Inc. 85 Broad St. New York NY 10004	2202	89621.40	48721701	10/08/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary shares	10/08/2026	Shares issued upon vesting of RSUs	UroGen Pharma Ltd.			8966	10/08/2026	No consideration, shares issued upon vesting of RSUs

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	_x000D_ Shares sold to cover tax withholding obligations upon vesting of equity awards.
Date of Notice	10/08/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Christopher Degnan By: /s/ Meirav Shemesh Title: Authorized Signatory, Oppenheimer Israel (pursuant to delegation)
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)